Australia’s Modern Gold Rush: Hobby Prospectors Flock to Victoria’s Golden Triangle 
SoftBank Completes $41 Billion OpenAI Investment in Historic AI Funding Round 
Air China Orders 60 Airbus A320neo Jets in $9.5 Billion Deal as Airbus Strengthens Grip on China Market 
Samsung Electronics Secures Annual U.S. Licence for China Chip Equipment Imports in 2026 
Boeing Secures Major $2.7 Billion U.S. Military Contract for Apache Helicopter Support 
Citigroup to Exit Russia With Sale of AO Citibank to Renaissance Capital 
Elon Musk’s xAI Expands Supercomputer Infrastructure With Third Data Center to Boost AI Training Power 
Baidu Shares Surge as Company Plans Kunlunxin AI Chip Spin-Off and Hong Kong Listing 
Lockheed Martin Secures $328.5 Million U.S. Defense Contract for Advanced Systems Supporting Taiwan Air Force 
Nike Stock Rises After CEO Elliott Hill Buys $1 Million in Shares 
Starlink Plans Satellite Orbit Reconfiguration in 2026 to Boost Space Safety 
Neuralink Plans High-Volume Brain Implant Production and Fully Automated Surgery by 2026 
Hyundai Faces Deadline on Russia Plant Buyback Amid Ukraine War and Sanctions 
Google Accelerates AI Infrastructure With Ironwood TPU Expansion in 2026 
Bain Capital Moves to Acquire Majority Stake in Echo Marketing 
Target Stock Rallies as Activist Interest Sparks Hopes for Strategic Change 
NEW YORK, March 13, 2017 -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of Psychemedics Corporation securities (NASDAQ:PMD) from February 28, 2014 through January 30, 2017, inclusive (the “Class Period”) of the important April 3, 2017 lead plaintiff deadline in the class action. The lawsuit seeks to recover damages for Psychemedics investors under the federal securities laws.
To join the Psychemedics class action, go to http://rosenlegal.com/cases-1047.html or call Phillip Kim, Esq. or Kevin Chan, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.
NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE.
According to the lawsuit, throughout the Class Period Defendants made false and/or misleading statements and/or failed to disclose that: (1) through its affiliate Psychemedics Brasil Exames Toxicologicos Ltda., Psychemedics engaged in anticompetitive conduct to maintain a monopoly over the Brazilian market in violation of the law; (2) in turn, Psychemedics lacked effective internal controls over financial reporting; and (3) as a result, Psychemedics’ public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.
A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than April 3, 2017. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to http://rosenlegal.com/cases-1047.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim, Esq. or Kevin Chan, Esq. of Rosen Law Firm toll free at 866-767-3653 or via e-mail at [email protected] or [email protected].
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm.
Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Attorney Advertising. Prior results do not guarantee a similar outcome.
Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. Kevin Chan, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 34th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 [email protected] [email protected] [email protected] www.rosenlegal.com
